ArriVent's lung cancer treatment fails late-stage trial
06/10/2026 13:07
ArriVent's lung cancer treatment fails late-stage trial Oct 6 (Reuters) - ArriVent BioPharma AVBP.O said on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Devika Syamnath)
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal